Samsung Bioepis has announced US Food and Drug Administration (FDA) approval for PYZCHIVA (ustekinumab-ttwe / SB17) as a biosimilar to Stelara (ustekinumab). The approval includes subcutaneous ...
May 5 () - CVS Health said on Tuesday it would prefer lower-cost, interchangeable biosimilars ‌over Johnson & Johnson's ...
CVS announced Tuesday it will expand its use of lower-cost biosimilars and tr | The move to prioritize biosimilars comes as ...
Ustekinumab is a human interleukin-12 and -23 antagonist indicated for multiple chronic inflammatory diseases. A biosimilar is a biological product that is approved based on data demonstrating that ...
Hosted on MSN
CVS to expand biosimilar use in July to cut costs
Biosimilars replace brands: From July 1, CVS will prioritize FDA-approved biosimilars like Pyzchiva and Yesintek over Stelara on its main formularies. Lower costs promised: Most CVS members are ...
The approval was based on a totality of evidence, including data from a phase 3 study (ClinicalTrials.gov Identifier: NCT04967508) that compared the efficacy and safety of Pyzchiva to the reference ...
(RTTNews) - Sandoz Group AG (SDZNY), a Swiss maker of generic and biosimilar medicines, announced Monday that the US Food and Drug Administration has approved biosimilar Pyzchiva (ustekinumab-ttwe), ...
(RTTNews) - Sandoz Group AG (SDZNY.OB), a Swiss company that focuses on generic pharmaceuticals and biosimilars, today announced the approval of Pyzchiva. The FDA has granted approval to Pyzchiva, a ...
Please provide your email address to receive an email when new articles are posted on . Pyzchiva, an ustekinumab biosimilar, is approved for all indications of the reference medicine, including ...
Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in Europe commercially available in an autoinjector. Developed and registered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results